The Transmucosal Height Trade-Off: Crestal Bone Preservation Versus a Deeper Mucosal Tunnel
- Paper type
- Hypothesis and Theory (with a factorial trial protocol)
- Status
- Original Work · Working Paper
- Keywords:
- transmucosal abutment height · mucosal tunnel depth · marginal bone loss · peri-implant mucositis · supracrestal tissue height · factorial randomized trial · trade-off model
Contents
Abstract
Background. Two bodies of evidence on the height of the transmucosal segment of an implant restoration point in opposite directions. Taller abutments are associated with less early crestal bone loss, and independent factorial trials suggest that abutment height, rather than native mucosal thickness, carries most of this effect. Separately, a deeper mucosal tunnel is associated with slower resolution of experimental peri-implant mucositis and with harder biofilm access. The two lines have not been tested in one design.
Hypothesis. Increasing transmucosal height lowers early remodeling bone loss with diminishing returns while raising later inflammatory burden, so that total long-term harm is minimized at an intermediate height, and bone-level endpoints at 1 year systematically favor the tallest design.
Proposed approach. We formalize the idea as an explicit model (saturating early loss, increasing inflammatory hazard, weighted total harm, and a closed-form condition for an interior optimum), with every functional form labeled as an assumption. We propose a stratified 2 × 3 factorial randomized trial (native vertical mucosal thickness × transmucosal height of 1, 2 and 3 mm; one definitive abutment placement in every arm) with an experimental-mucositis challenge at 1 year and disease endpoints to at least 5 years, and we give sample-size calculations for the interaction and for the long-term inflammatory endpoint, checked by script.
Expected contribution. A set of numbered, falsifiable predictions; a measurement argument for why 1-year bone data are biased toward tall designs; and an honest estimate of how shallow the optimum may be. An illustrative computation shows that the model yields an interior optimum only within a narrow band of parameter ratios and that total harm may differ by only a few percent across 1 to 3 mm.
Conclusions. The early-bone leg of the trade-off is reasonably supported; the late-harm leg is supported for mucositis resolution and hygiene access but not for peri-implantitis, where the only long-term randomized signal points the other way. The hypothesis is therefore testable but not established, and the proposed trial is large.
1. Introduction
The vertical dimension between the implant platform and the mucosal margin has been framed mainly as a threat to bone. When the mucosal seal is too short, bone remodels apically to make room for it, and that remodeling is visible on radiographs within the first year after loading [1–3]. A clinician reading this literature learns to prefer thick tissue or tall abutments.
A second literature frames the same dimension as a threat to the mucosa. The space between the margin and the platform is a tunnel through which biofilm must be controlled, and a deeper tunnel is harder to clean and slower to recover from experimental inflammation [4, 5]. A clinician reading this literature learns to avoid deep tunnels.
Both messages are reasonable and both come from careful studies. They conflict only when the same design variable, transmucosal height, is asked to serve two purposes. This manuscript treats that conflict as a quantitative trade-off and asks whether it creates an interior optimum. It makes three contributions. First, it sets the two evidence lines side by side and names the main bias in each. Second, it states a small mathematical model whose assumptions are explicit and whose optimum condition is checkable. Third, it specifies a factorial trial that could discriminate the trade-off from simpler explanations.
Two features of the problem need to be stated at the outset. The outcome that most trials report, marginal bone level at 1 year, is also the outcome the tall design is built to improve, so bone-level endpoints are structurally favorable to height. And the diagnostic definition of peri-implantitis includes bone loss, which couples the two legs of the trade-off through the case definition [6]. Both features are developed in Section 3.
No experiment, clinical study, or patient-data analysis was performed. Appraisal is from PubMed abstracts, Europe PMC records and ClinicalTrials.gov entries retrieved on 17 November 2026; Embase, Scopus and Web of Science were not accessible, and full texts were not read.
2. Background and critical appraisal of the evidence
Origin of the concept
The idea that peri-implant mucosa needs a minimum vertical dimension descends from histological work on the soft tissue barrier at implants and teeth [7] and from the biological width concept applied to one- and two-piece titanium implants [8]. A dog experiment that reduced the mucosal height and observed bone resorption during healing is the usual experimental anchor [3]. Human trials from one clinical group then reported that thin mucosa at placement was followed by roughly a millimeter or more of early bone loss, whereas thick mucosa was followed by much less [9, 10]. A related line reported that vertical thickening of thin mucosa was followed by less loss [11, 12]. These studies established the clinical rule of thumb that at least 2 mm of vertical mucosal thickness is desirable.
The same studies carry a confound that later work exposed. In the 2009 trial, test implants were also placed about 2 mm more supracrestally than the comparison implants, so thickness and implant position were not independent [9]. In the thickening trials, the thickened arm differed from the others in staging of surgery [11], and the only randomized thickening trial compared two thickening techniques without an untreated control [12].
Abutment height as the competing explanation
A cluster randomized trial of 70 platform-switched implants crossed abutment height with mucosal thickness and reported bone loss of 0.59 to 0.80 mm with short abutments and 0.28 to 0.37 mm with long abutments at 12 months after loading, irrespective of vertical thickness [13]. An 80-patient randomized trial with 18-month follow-up reached the same conclusion [14]. A 1-year randomized trial of 99 implants with 1-mm or 3-mm abutments found that mucosal thickness did not correlate with bone change [15]. In a prospective controlled trial of tissue-level implants, no thin versus thick difference emerged in 26 completers [16]. Observational work earlier had already shown that abutment height below 2 mm was associated with higher bone loss, that loss followed a nonlinear course with most of it in the first 6 months after loading [2], and that the loss could be annulled at an abutment height of about 2.5 to 3.0 mm depending on implant neck design [17]. The abutment-height signal is thus both consistent and shaped like a saturating function, which is the property the model in Section 3 uses.
Evidence syntheses are less decisive on thickness. A meta-analysis of six studies and 354 implants reported a difference of 0.54 mm at 10 to 14 months, and trial-sequential analysis indicated that more trials were needed [18]. Another meta-analysis found 0.41 mm in the short term but only 0.17 mm and no significance at 3 years or more [19]. An earlier systematic review concluded that evidence was insufficient and that no low-risk-of-bias study existed [20], and a further meta-analysis addressed early bone loss [21]. A systematic review of abutment height itself flagged unresolved confounding among included studies [22]. The AO/AAP review concluded that abutment heights of at least 2 mm were associated with less bone loss than shorter heights [23].
Thickness is not irrelevant everywhere. In tissue-level implants, multicenter prospective studies still reported more loss in thin mucosa [24, 25], and a randomized trial from the original group found subcrestal placement to outperform tissue “tenting” [26]. We read the full picture as follows: abutment height has a replicated effect on early loss; native thickness has a smaller effect that is hard to separate from implant position, implant type and abutment height; and the evidence is short term.
The one abutment–one time protocol as a related confound
Repeated abutment disconnection was proposed to disturb the mucosal seal, and an early dog study reported apical shift and bone loss after repeated removal [27]. Human trials are mixed. A 5-year randomized trial did not find a significant benefit of one-time placement [28], whereas a 12-month trial found less loss with one-time placement but with taller abutments in that arm [29]. A six-arm trial reported the lowest bone loss with immediate abutments of 2 to 3 mm, and higher loss with 1.5-mm immediate abutments or any delayed abutment [30]. A meta-analysis found that long abutments helped irrespective of connection timing [31]. The AO/AAP review nevertheless reported less loss with a one abutment–one time protocol [23]. For our purposes the lesson is narrow: arms that differ in timing also tend to differ in abutment height or loading, so the timing effect cannot be assumed to be independent of height. Any trial of height must therefore fix the abutment protocol in all arms.
The mucosal tunnel and inflammation
Resolution of inflammation, not its induction, is where tunnel depth appears to matter most. In the experimental mucositis study of 19 subjects with tissue-level implants, tunnels of at least 3 mm were compared with tunnels of 1 mm or less [4]. Plaque and gingival indices rose together during a 3-week induction phase. After oral hygiene resumed, plaque resolved in both groups, but inflammation resolved later and less completely around deep tunnels, interleukin-1β was higher, and removal of the crown with submucosal cleaning was needed to return the gingival index to baseline [4]. The design is a small case-control comparison without randomization of tunnel depth [4].
Supporting observations are consistent in direction but weak in design. A critical review concluded that a sulcus depth of at least 3 mm reduced the effectiveness of mucositis treatment, and also that evidence on design elements was limited, inconsistent in definitions and outcome measures, and in need of purpose-designed studies [5]. A cross-sectional study of 122 subjects found that crown emergence angle, profile and depth of the mucosal tunnel were each associated with detectable plaque and bleeding on probing [32]. In an exploratory cross-sectional study of cultivable flora, tunnels deeper than 5 mm showed lower cultivable diversity and higher local tumor necrosis factor-α expression, which the authors cautioned was a biological association rather than evidence of disease [33]. A clinical study of 39 implants found that in-mouth ultrasonic cleaning removed less than half of the plaque and performed worse when probing depth exceeded 5 mm [34], and an in vitro study addressed emergence angle and tunnel depth in biofilm removal [35]. None of these studies randomized height.
Evidence that complicates the late-harm leg
Three findings argue against assuming that height raises long-term disease. First, in a 5-year cohort analysis of 25 tissue-level implants, greater supracrestal tissue height was associated with less mucositis (odds ratio 0.50), and a threshold of 2.8 mm was proposed for long-term health [36]. Second, in a 7-year randomized trial of 1-mm versus 3-mm definitive abutments on subcrestally placed implants, 63 implants were analyzed. Peri-implantitis occurred in 18.2% of 1-mm implants and 3.2% of 3-mm implants, whereas mucositis occurred in 54.6% and 74.2%, and the differences were not significant, so the authors drew no conclusion about protection against peri-implantitis [37]. Third, in a 12-month cohort of 60 implants in patients with controlled periodontitis, tunnel depth was not associated with probing depth or bone loss [38]. A fourth observation runs the other way: in patients with a history of periodontitis, greater vertical soft-tissue thickness was associated with higher probing depth and bone loss, with odds ratios around 2.5 [39].
Taken together, the mucositis data lean toward the trade-off and the peri-implantitis data do not. The hypothesis in Section 3 is built on that asymmetry: late harm is taken to act through the inflammatory pathway the experiments identify, and its link to peri-implantitis is treated as an open empirical question.
| Study | Design and size (from abstract) | Finding relevant here | Main bias or limit | Level |
|---|---|---|---|---|
| Spinato 2019 [13] | Cluster RCT, 70 implants, 12 months after loading | Abutment height, not thickness, governs early loss | Short term; private practices; implant type specific | B |
| Spinato 2020 [14] | RCT, 80 patients, 18 months | Same | Short term | B |
| Muñoz 2021 [15] | RCT, 99 implants, 1 year | Thickness uncorrelated with bone change at 1 vs 3 mm | Subcrestal placement; 1 year | B |
| Muñoz 2025 [37] | RCT follow-up, 63 implants at 7 years | 3 mm kept bone; disease differences not significant | Attrition; underpowered for disease | B/C |
| Chan 2019 [4] | Case-control, 19 subjects, experimental mucositis | Deep tunnel delays resolution | Small; not randomized; tissue-level | C |
| Sabri 2026 [36] | Cohort analysis, 25 tissue-level implants, 5 years | Greater supracrestal height protective for mucositis | Very small; secondary analysis | C |
| Zhang 2020 [39] | Prospective cohort, 65 patients, over 2 years | Thicker mucosa linked to peri-implantitis | Periodontitis history only | C |
| Mattheos 2021 [5] | Critical review | Sulcus depth at least 3 mm lowers mucositis treatment success | Inconsistent definitions | C |
| Spinato 2018 [17] | Clinical comparison with regression | Bone loss annulled at about 2.5–3.0 mm abutment height | Observational; cement-retained | C |
| Lin 2025 [23] | AO/AAP systematic review and meta-analysis | Abutments of 2 mm or more: less loss | Confounding among included studies | B |
Evidence levels are operational categories used in this manuscript (A strong, B moderate, C preliminary, D mechanistic or theoretical, E speculative), not GRADE ratings. Appraisal is at abstract level.
3. Hypothesis and theoretical framework
Formal statement
Hypothesis H1. For a single implant restored with one definitive abutment placed once, and with crown contour, loading and maintenance held constant, increasing transmucosal height h (i.e., abutment or collar height above the implant platform, in mm) (a) reduces early remodeling bone loss with diminishing returns and (b) increases the later burden of peri-implant inflammation, so that the height minimizing expected total harm over a long horizon is intermediate and lies below the height that minimizes 1-year bone loss.
For bone-level implants placed subcrestally by depth s (mm), the mucosal tunnel depth is d = h + s. In this manuscript h is the quantity that is randomized; s is fixed by protocol; and tunnel depth is treated as the biological mediator of h. This distinction matters because the literature on abutment height and the literature on tunnel depth use different variables for what is partly the same dimension.
Assumptions
All functional forms below are assumptions chosen for tractability, not estimates from data.
- A1 (early term). Expected early remodeling loss is a decreasing, convex, saturating function of h, written L(h)=L_0e^(−h/τ) with L_0>0 in mm and τ>0 in mm. This reflects the replicated observation that short abutments lose more bone, that loss falls with height, and that it can approach zero at about 2.5 to 3 mm in some implant designs [2, 17].
- A2 (late term). The hazard of a persistent inflammatory state (persistent mucositis, or its progression) is increasing in h, written λ(h)=λ_0e^(γh) with λ_0>0 per year and γ>0 per mm. This reflects reduced hygiene access and delayed resolution in deeper tunnels [4, 5, 34].
- A3 (additivity). Total harm is the weighted sum of the two terms, with no interaction between them. In reality bone loss exposes more implant surface and may itself raise inflammatory risk, and bone loss is part of the peri-implantitis case definition [6]; A3 is a simplification we revisit in Section 5.
- A4 (horizon). The inflammatory term accumulates over T years of follow-up, with constant hazard in time.
- A5 (weights). The weights wB (harm per mm of early bone loss) and wI (harm per unit cumulative hazard) are patient- and clinician-dependent value judgments, not biological constants.
The model
Total expected harm is
H(h)=w_B L_0e^(−h/τ)+w_I T λ_0e^(γh).
Differentiating,
H′(h)=−w_BL_0/τe^(−h/τ)+w_ITλ_0γ e^(γh).
Because the first term of H′ is negative and increasing toward zero while the second is positive and increasing, H′ is strictly increasing and crosses zero at most once. Since H′(0)=−w_BL_0/τ+w_ITλ_0γ, an interior minimum exists at h^*>0 if and only if
w_BL_0/τ>w_I T λ_0 γ.
In words, the marginal early-bone benefit of the first millimeter of height must exceed the marginal late inflammatory cost of that millimeter. When it holds,
h^*=1/(γ+1/τ)ln(w_BL_0/(τ w_I T λ_0 γ)).
Three properties follow. First, the bone-only minimizer is the tallest feasible design, so any endpoint that counts only bone favors tall designs. Second, h^* rises with the bone weight and with L_0 and falls with the horizon T, the baseline hazard λ_0, the inflammatory growth rate γ and the inflammatory weight. Third, with rate k=γ+1/τ, the optimum falls inside a clinically relevant window (h_a,h_b) if and only if the ratio B/A of the late marginal cost to the early marginal benefit at h=0 lies between e^(−kh_b) and e^(−kh_a). The window is narrow.
Illustrative computation under stated assumptions — not empirical data
The script tradeoff_calc.py (saved with this manuscript and run for this paper) calibrates A1 to two anchor values and then evaluates scenarios. The anchors are 0.70 mm of early loss at h = 1 mm and 0.33 mm at h = 3 mm; they are rounded from the ranges reported in one trial of platform-switched implants [13] and are used here only to fix the shape of the curve. The script output was: τ = 2.660 mm, L0 = 1.020 mm, and L(h) of 1.020, 0.700, 0.481, 0.330, 0.227 and 0.156 mm at h = 0 to 5 mm. The increments of the curve are 0.219 mm from 1 to 2 mm and 0.151 mm from 2 to 3 mm. The saturation is therefore gentle in the 1 to 3 mm range under this calibration.
For the late term we set wB = 1 per mm, T = 5 years, λ0 and γ as listed, and varied wI. These values are invented to explore the model’s behavior; none is an estimate of a real hazard.
| Scenario | wI | λ0 (per year) | γ (per mm) | Early marginal benefit A | Late marginal cost B | Interior optimum | h* (mm) | H at 1 mm | H at h* | H at 3 mm |
|---|---|---|---|---|---|---|---|---|---|---|
| Weak late harm | 2.0 | 0.05 | 0.10 | 0.383 | 0.050 | Yes | 4.28 | 1.253 | 0.971 | 1.005 |
| Intermediate | 1.7 | 0.08 | 0.20 | 0.383 | 0.136 | Yes | 1.80 | 1.531 | 1.493 | 1.569 |
| Moderate | 4.0 | 0.08 | 0.20 | 0.383 | 0.320 | Yes | 0.31 | 2.654 | 2.610 | 3.245 |
| Strong | 6.0 | 0.10 | 0.35 | 0.383 | 1.050 | No | 0 | 4.957 | 4.020 | 8.903 |
Output of tradeoff_calc.py. H is in arbitrary units. Not empirical data.
The table supports four observations. First, the interior optimum is not generic: in the weak scenario it lies beyond the practical range (4.28 mm), in the moderate and strong scenarios at or near zero, and only in the intermediate scenario inside 1 to 3 mm. For γ = 0.20 per mm the window [1, 3] mm requires B/A between 0.178 and 0.562 (script output). Second, even when the optimum is interior, the loss curve around it is flat: in the intermediate scenario, total harm is 1.531 at 1 mm, 1.493 at the optimum and 1.569 at 3 mm, differences of a few percent. Third, the model reverses the ordering of designs depending on the horizon and weights, which is the substance of the “endpoint bias” claim. Fourth, the model gives no reason to expect a large clinical effect unless late harm is steep. A trade-off could exist and still be of modest practical importance.
Why one-year bone data favor the taller design
Consider a trial with follow-up at 1 year after loading and a primary bone endpoint. Under A1, the expected difference in bone loss between heights h_1<h_2 is L_0(e^(−h_1/τ)−e^(−h_2/τ))>0. Under A2, the inflammatory difference grows with T and is near zero at 1 year, since the hazard has not yet accumulated. A 1-year bone endpoint thus samples only the first term of H. If the trial reports no inflammatory outcome, it will conclude that taller is better, whatever the value of h^*. The same logic applies to systematic reviews that pool short-term bone endpoints.
A second mechanism strengthens the bias. If peri-implantitis is defined partly by radiographic bone loss from a baseline [6], then a design that lowers early remodeling lowers the probability of crossing the bone threshold without necessarily lowering inflammation. A low peri-implantitis rate with tall abutments, as observed in point estimates at 7 years [37], is therefore compatible both with real protection and with a definitional artifact. The trial in Section 4 resolves this by pre-specifying bone-independent inflammatory endpoints.
Mechanistic rationale for the late term
Three mechanisms could make γ positive. The first is access: a longer subgingival crown or abutment surface leaves more surface in a sulcus that a brush or interdental device reaches poorly, and ultrasonic cleaning in deep sites removes less plaque [34, 35]. The second is ecology: deeper tunnels showed different cultivable flora and higher local cytokine expression, though the authors state that this is not evidence of disease [33]. The third is contour: emergence angle and profile were associated with plaque and bleeding alongside tunnel depth [32], and emergence profile and tissue height are interrelated features of the supracrestal complex [40]. A taller transmucosal segment can be given a favorable contour, so the contour mechanism is a competitor rather than a part of the height effect, and the design must fix it.
None of these mechanisms predicts that height causes peri-implantitis. They predict slower recovery from a bacterial challenge and a higher chance that a mucositis episode persists, which is a precursor condition rather than the disease. That is why the primary late endpoint proposed below is persistent mucositis, with peri-implantitis as a secondary endpoint.
Numbered predictions and refuting results
- P1. At equal native thickness, 1-year bone loss decreases from 1 to 2 to 3 mm of transmucosal height. Refuted if 3-mm implants lose as much as or more than 1-mm implants, in which case the early-bone leg fails in this population.
- P2. The decrement is smaller from 2 to 3 mm than from 1 to 2 mm (curvature). Refuted if the 2-to-3 increment equals or exceeds the 1-to-2 increment. We note in Section 4.6 that the trial is not powered to detect curvature in bone alone.
- P3. At 3 mm of height, native thickness changes 1-year bone loss by less than 0.3 mm (no height × thickness interaction at or above 0.3 mm). Refuted if thin mucosa at 3 mm loses at least 0.3 mm more than thick mucosa, which would restore a thickness effect independent of abutment height [9, 10].
- P4. Time to resolution of experimental mucositis and the area under the interleukin-1β curve increase with height. Refuted if resolution is equal or faster at 3 mm than at 1 mm [4, 36].
- P5. The 5-year cumulative incidence of persistent mucositis (bone-independent definition) is higher at 3 mm than at 1 mm. Refuted if the hazard ratio for 3 versus 1 mm is 1.0 or lower with a confidence interval excluding 1.5.
- P6. A rank reversal occurs: the 3-mm arm ranks best on 1-year bone loss but not best on the 5-year composite harm. Refuted if 3 mm ranks best on both.
- P7. Defining peri-implantitis without a bone criterion moves the 3-mm versus 1-mm hazard ratio toward or above 1 relative to the bone-inclusive definition. Refuted if the two definitions give the same hazard ratio, which would remove the definitional-artifact explanation.
If P1 and P3 hold while P4 to P6 fail, the evidence would favor the simple view that taller is better and the trade-off hypothesis would be rejected. If P4 and P5 hold but P6 fails, the late harm exists but is too small to outweigh the early benefit at the weights used.
4. Proposed methodology
Design
We propose a multicenter, parallel-group, stratified randomized trial with a 2 × 3 factorial structure. One factor is native vertical mucosal thickness at the planned crestal position (thin, 2 mm or less; thick, more than 2 mm), measured at surgery by a standardized probe or needle technique, which is a stratification factor and cannot be randomized. The other is offered transmucosal height (abutment height of 1, 2 or 3 mm), allocated at random within each thickness stratum with concealed allocation. Every arm receives a single definitive abutment placed once, at the same time point relative to surgery, so that the one abutment–one time effect and loading time cannot vary between arms [27–31]. Because thickness is not randomized, the interaction estimates effect modification by a baseline characteristic, not a causal effect of thickness. The design therefore tests whether height effects differ by stratum, the question raised by the factorial trials [13, 14].
The schedule is shown in Figure 2.
Population and fixed co-interventions
Adults with a single missing premolar or molar and a healed ridge; platform-switched, bone-level implants with an internal conical connection of one system, placed equicrestally by the same protocol; adequate keratinized mucosa; no grafting to thicken mucosa; periodontitis, if present, treated and stable; smoking limited by protocol. Contour is fixed: a CAD/CAM crown with a straight or concave emergence profile and an emergence angle below 30 degrees, a design associated with lower peri-implantitis risk in the AO/AAP review [23], with measurement of the realized angle at each visit [32]. Loading, cement or screw retention, and the maintenance schedule (professional care every 6 months) are identical across arms. Implants with thin mucosa and a 3-mm abutment will have a supramucosal abutment segment, so the realized tunnel depth d is measured at the 3-month, 1-year and 5-year visits and is reported as a manipulation check and as a candidate mediator. This is necessary because the offered height and the realized tunnel depth are not the same quantity when mucosa is thin.
Measurements and their validity
Bone. Standardized parallel-technique digital periapical radiographs with a calibrated reference dimension (the implant), taken at loading and at 1, 3 and 5 years. Mesial and distal levels are measured to the platform by two blinded examiners, with the mean per implant as the unit. Projection error remains despite the fixed implant landmark. A random subset is read twice to estimate intra-examiner agreement.
Inflammation, clinical. Bleeding on probing, suppuration and probing depth at six sites per implant at every visit, by a calibrated examiner blinded to height where the abutment is covered by the crown. Because the crown reveals little about height, blinding is feasible for examiners but not for operators.
Inflammation, experimental. In a nested sub-study at 1 year, an experimental mucositis challenge modeled on the published protocol [4]: oral hygiene optimization, a 3-week induction phase with an acrylic stent limiting self-performed hygiene at the study implant, and a resolution phase of 3 plus 2 weeks, with plaque and gingival indices and peri-implant sulcus fluid interleukin-1β. This yields time to resolution and cytokine area under the curve. It requires specific ethics approval, informed consent, and a rescue plan, since the challenge deliberately induces reversible inflammation.
Disease endpoints. Peri-implant mucositis and peri-implantitis are classified according to the 2017 World Workshop definitions [6] and interpreted with the AO/AAP consensus framework [41]. The primary late endpoint is persistent mucositis, defined without any bone criterion as bleeding on probing at the study implant on two consecutive visits at least 3 months apart. Peri-implantitis is a secondary endpoint analyzed twice, with and without the radiographic bone-loss criterion, which is the basis of P7. Radiographic bone loss has long been part of implant success criteria [42], which is why a bone-independent inflammatory endpoint is needed to avoid circularity.
Covariates. Smoking, periodontitis history, keratinized mucosa width, hygiene compliance, implant position, realized emergence angle and tunnel depth.
Endpoint hierarchy
- Primary: 5-year cumulative incidence of persistent mucositis, 3 mm versus 1 mm (P5).
- Key secondary: 1-year bone loss, height × thickness interaction (P3), and the main height effect (P1).
- Secondary: experimental-mucositis resolution (P4); the composite harm H under a pre-registered grid of weights wB and wI (P6); peri-implantitis with and without the bone criterion (P7).
- Exploratory: curvature of bone loss (P2); mediation by realized tunnel depth; abutment-related technical complications.
Hierarchical (gatekeeping) testing at a two-sided 5% level controls multiplicity along this list. The composite harm is not a single patient-level quantity; it is computed under several weight pairs elicited from clinicians and patients in a separate preparatory step, and reported as a sensitivity surface.
Statistical analysis plan
Bone loss is analyzed with a linear mixed model with fixed effects for height (1, 2, 3 mm), thickness stratum and their interaction, adjustment for center and baseline covariates, and a random effect for center; one implant per patient avoids clustering within patients. Time to persistent mucositis and to peri-implantitis is analyzed with Cox models and cause-specific hazards, treating implant failure and loss to follow-up for reasons related to disease as competing events and censoring other dropouts, with sensitivity analyses by multiple imputation and by a tipping-point analysis. The analysis is by intention to treat for the allocated height, with a per-protocol analysis restricted to implants whose realized tunnel depth is within 0.5 mm of the allocation. The statistician is blinded to arm labels until the analysis plan is locked.
Sample-size reasoning
All inputs below are planning assumptions, not estimates from our own data. Calculations were run in Python (scipy) and are reproduced in tradeoff_calc.py.
Interaction on 1-year bone loss. For a 2 × 2 contrast of 1 mm versus 3 mm across the two thickness strata, the interaction estimate is δ=(y_(11)−y_(12))−(y_(21)−y_(22)) with standard error 2σ/√(n) for n implants per cell. The sample size per cell for two-sided α = 0.05 and power 0.80 is
n=(4σ^2 (z_(1−α/2)+z_(1−β))^2)/(Δ^2),
with z_(0.975)=1.9600 and z_(0.80)=0.8416. We take Δ = 0.3 mm because it is a planning threshold for the smallest interaction worth detecting (a difference of that size would restore a thickness effect independent of abutment height), and σ = 0.5 mm, a planning value for the between-implant standard deviation of 1-year loss. The script returned 87.2 implants per cell, rounded up to 88; with 15% attrition, 104 per cell. For the 2 × 3 design the same contrast applies to the 1-versus-3-mm comparison, and the 2-mm cells add a total of two cells, so 6 × 104 = 624 randomized implants. If Δ = 0.4 mm the figures are 49.1 (50) per cell, 59 with attrition and 354 in total; if σ = 0.6 mm and Δ = 0.3 mm they are 125.6 (126), 149 and 894.
Curvature. The quadratic contrast on the calibrated curve of Table 2 is 0.0688 mm. With σ = 0.5 mm, the script returned 1,245 implants per cell for 80% power, or about 2,491 per height level. The trial is therefore not designed to test curvature of bone loss, and P2 is exploratory. The interior optimum can only be supported through the composite H and through the rank reversal in P6.
Late inflammatory endpoint. For a two-group comparison of 5-year cumulative incidence with a planning contrast of 0.55 versus 0.74 for persistent mucositis, taken only as a rough analogue of the mucositis proportions in the 7-year trial [37], the script returned 98.4 per group, rounded up to 99, and 132 per group with 25% attrition by year 5. For 0.55 versus 0.70 the corresponding values are 163 and 218, and for 0.50 versus 0.65 they are 170 and 227. Under a time-to-event framing with Schoenfeld’s formula d=4(z_(1−α/2)+z_(1−β))^2/(lnHR)^2, a hazard ratio of 1.5 requires 191 events; 1.4 requires 278 and 1.7 requires 112. With 45% of the 1-mm arm and 59.2% of the 3-mm arm expected to have an event by year 5 (the second value derived from the assumed hazard ratio), about 367 patients are needed, or 489 allowing 25% attrition. For the peri-implantitis proportions of the 7-year trial (0.18 versus 0.03) [37], 65 per group (87 with attrition) would be needed to detect a reversal in favor of the tall abutment, which shows that the opposite hypothesis is cheaper to test than ours.
Nested challenge. For a standardized effect of 0.8 on time to resolution between 1-mm and 3-mm arms, about 25 implants per arm are required at 80% power; the effect size is a planning value, because the published study was too small to provide a reliable estimate [4].
| Question | Assumptions | Per cell or group | With attrition | Total |
|---|---|---|---|---|
| Interaction, 1-year bone | σ 0.5 mm, Δ 0.3 mm, 80% power | 88 | 104 | 624 (2 × 3) |
| Interaction, 1-year bone | σ 0.5 mm, Δ 0.4 mm | 50 | 59 | 354 (2 × 3) |
| Curvature of bone loss | σ 0.5 mm, quadratic contrast 0.0688 mm | 1,245 | not computed | not feasible |
| Persistent mucositis, 5 years | 0.55 vs 0.74 | 99 | 132 | 264 (two arms) |
| Persistent mucositis, 5 years | 0.55 vs 0.70 | 163 | 218 | 436 (two arms) |
| Time to event | HR 1.5, 191 events | not applicable | 489 (25% attrition) | 489 |
| Reversal check, peri-implantitis | 0.18 vs 0.03 | 65 | 87 | 174 |
Totals for the first two rows come from 6 × the attrition-adjusted cell size; totals for proportion rows are twice the attrition-adjusted per-group size.
Bias control, ethics and feasibility
Randomization is stratified by thickness and center with permuted blocks and central concealment; the operator cannot be blinded. Radiograph readers are blinded to arm, and calibration is verified with weighted kappa or intraclass correlation before and during the trial. Registration before enrollment would be required; no registration exists for this protocol, and none is claimed. A search of ClinicalTrials.gov on 17 November 2026 found abutment-shape and height trials and tissue thickening trials but none whose entry described a height-by-thickness factorial with disease follow-up; entries were reviewed by title only, and this negative finding is not exhaustive. Feasibility is the largest concern: a 624-implant trial with 5 years of follow-up is a multicenter effort, and the proposal is staged in Section 8.
5. Competing explanations and how the design discriminates among them
Height is monotonically protective for every endpoint. This is the simplest alternative, and the 7-year trial’s peri-implantitis point estimates are compatible with it [37]. The design separates it from H1 through P4 and P5: a positive height gradient in persistent mucositis with an inverse gradient in bone loss rejects it, while a flat or negative gradient in both rejects H1.
Contour, not height, drives late inflammation. Emergence angle and profile relate to plaque and bleeding [32], and tissue height and contour are interrelated [40]. Fixing the crown contour and recording the realized angle makes height the only designed difference; if the height effect on mucositis vanishes after adjustment for realized angle, contour is the explanation.
Native thickness acts through baseline tissue quality. If thin mucosa predicts bone loss only when the abutment is short, P3 holds and the thickness effect is height-dependent [13–15]. If an effect persists at 3 mm, the tissue-level data [24, 25] are the better guide and the thickness rule is partly restored.
One abutment–one time, loading and connection artifacts. These are removed by design, not by analysis, which is the reason for a single placement protocol [27–31].
Radiographic and definitional artifact. Early bone loss on films can reflect remodeling to establish a seal and not inflammation, and a bone-inclusive peri-implantitis definition inflates the benefit of tall designs. P7 and the bone-independent endpoint address this.
Cleansability versus biology of the seal. A deeper tunnel may be harder to clean (mechanical) or may carry a different local immune response [33] (biological). The experimental challenge probes the first because hygiene is controlled; persistent mucositis under standard maintenance probes the sum.
Population dependence. Associations differ with periodontitis history [38, 39] and implant type [36]; stratification by periodontitis history is a secondary analysis for which the study is not powered.
6. Clinical and engineering implications
These are conditional on the hypothesis being supported and are not current recommendations.
If H1 is supported with an optimum between 2 and 3 mm, restorative design could specify an intermediate transmucosal height for single implants in thin mucosa, If the late term proves negligible, current preferences for abutments of 2 mm or more [23] would stand and would be extended to the long term. If the late term dominates, the choice between a short abutment with early bone loss and a tall one with a deeper tunnel would turn on the patient’s capacity for hygiene and on maintenance intensity, and a hygiene-capacity-dependent specification would be reasonable.
For manufacturers and engineers, the model suggests that transmucosal geometry should be reported as a pair (height and realized tunnel depth) together with emergence angle, and that trials should publish both bone and inflammatory outcomes by height. Short-term bone pooling should not be read as evidence about the total effect of height, and if the optimum is as shallow as the illustrative model allows, the choice of height within a moderate range may matter little.
7. Limitations
The limitations fall into evidence, model and design categories.
Evidence. All appraisal is at abstract level. Numbers attributed to studies are those visible in abstracts, and some details that matter for interpretation (for example, how tunnel depth was measured, or the exact definition of peri-implantitis) may differ in the full texts. The evidence base on tunnel depth is dominated by one experimental study with 19 subjects [4], cross-sectional associations [32, 33] and in vitro or short clinical cleaning studies [34, 35]. The long-term randomized data on height [37] and the 5-year tissue-level cohort [36] are small and do not support the late-harm leg for peri-implantitis. No gray literature or conference proceedings were systematically searched, so a published statement of the trade-off could exist outside the sources searched (PubMed, Europe PMC, ClinicalTrials.gov).
Model. The exponential forms are conveniences. The true early loss function might have a threshold or plateau that is better described by a piecewise form, and the inflammatory hazard might be flat up to a critical depth and rise sharply beyond it, in which case the optimum would sit at the critical depth. Additivity (A3) ignores the feedback from bone loss to inflammation, and the weights are value judgments. The calibration in Section 3.4 uses two rounded anchors from one trial and is not an estimate of the population curve. The model clarifies what must be measured; it does not predict a clinically important effect.
Design. Thickness is not randomized, so the interaction is descriptive of effect modification. Offered height and realized tunnel depth differ in thin mucosa, and the manipulation check addresses this only partly. The trial requires more than 600 implants for the interaction and substantially more to examine curvature, and the 5-year attrition assumption of 25% may be optimistic. The persistent-mucositis definition is new for this purpose and needs validation against the disease-related definitions. The experimental challenge is ethically sensitive and is restricted to a nested sub-study. Generalizability is limited to single, platform-switched, bone-level implants with a controlled contour; tissue-level implants, splinted restorations and implants in patients with severe periodontitis or heavy smoking are outside the design, and the observational literature suggests they may behave differently [24, 25, 39].
8. Conclusions
Early crestal bone loss falls with taller transmucosal segments and shows signs of saturation, and the main evidence that thick native mucosa matters independently of abutment height is weak. A deeper mucosal tunnel delays resolution of experimental mucositis in a small study, with supporting but low-grade associations for plaque and local inflammation. We therefore propose, as a hypothesis, that total long-term harm is minimized at an intermediate height and that 1-year bone endpoints are biased toward the tallest design. The late-harm leg is the weaker one: the only long-term randomized trial found peri-implantitis point estimates favoring the taller abutment, and a 5-year cohort found greater supracrestal height protective. A simple model shows that the optimum is interior only under a narrow band of parameter ratios and may be shallow. The factorial trial specified here can test the hypothesis, and its predictions state what would refute it. The hypothesis should not change clinical practice until such data exist.
Cite this paper
Jain S, Gupta A. The Transmucosal Height Trade-Off: Crestal Bone Preservation Versus a Deeper Mucosal Tunnel. Working paper. Center for Implant Dentistry; 2026. Available from: https://bayareaimplantdentistry.com/clinician-research-and-publications/transmucosal-height-trade-off
References
- Galindo-Moreno P, León-Cano A, Monje A, Ortega-Oller I, O’Valle F, Catena A. Abutment height influences the effect of platform switching on peri-implant marginal bone loss. Clin Oral Implants Res. 2016;27(2):167-73. doi:10.1111/clr.12554 (opens in a new tab). PMID: 25678247 (opens in a new tab).
- Galindo-Moreno P, León-Cano A, Ortega-Oller I, Monje A, Suárez F, ÓValle F, et al. Prosthetic Abutment Height is a Key Factor in Peri-implant Marginal Bone Loss. J Dent Res. 2014;93(7 Suppl):80S-85S. doi:10.1177/0022034513519800 (opens in a new tab). PMID: 24621670 (opens in a new tab).
- Berglundh T, Lindhe J. Dimension of the periimplant mucosa. Biological width revisited. J Clin Periodontol. 1996;23(10):971-3. doi:10.1111/j.1600-051x.1996.tb00520.x (opens in a new tab). PMID: 8915028 (opens in a new tab).
- Chan D, Pelekos G, Ho D, Cortellini P, Tonetti MS. The depth of the implant mucosal tunnel modifies the development and resolution of experimental peri-implant mucositis: A case-control study. J Clin Periodontol. 2019;46(2):248-255. doi:10.1111/jcpe.13066 (opens in a new tab). PMID: 30638273 (opens in a new tab).
- Mattheos N, Janda M, Acharya A, Pekarski S, Larsson C. Impact of design elements of the implant supracrestal complex (ISC) on the risk of peri-implant mucositis and peri-implantitis: A critical review. Clin Oral Implants Res. 2021;32 Suppl 21:181-202. doi:10.1111/clr.13823 (opens in a new tab). PMID: 34642979 (opens in a new tab).
- Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, Camargo PM, et al. Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018;45 Suppl 20:S286-S291. doi:10.1111/jcpe.12957 (opens in a new tab). PMID: 29926491 (opens in a new tab).
- Berglundh T, Lindhe J, Ericsson I, Marinello CP, Liljenberg B, Thomsen P. The soft tissue barrier at implants and teeth. Clin Oral Implants Res. 1991;2(2):81-90. doi:10.1034/j.1600-0501.1991.020206.x (opens in a new tab). PMID: 1809403 (opens in a new tab).
- Hermann JS, Buser D, Schenk RK, Schoolfield JD, Cochran DL. Biologic Width around one- and two-piece titanium implants. Clin Oral Implants Res. 2001;12(6):559-71. doi:10.1034/j.1600-0501.2001.120603.x (opens in a new tab). PMID: 11737099 (opens in a new tab).
- Linkevicius T, Apse P, Grybauskas S, Puisys A. The influence of soft tissue thickness on crestal bone changes around implants: a 1-year prospective controlled clinical trial. Int J Oral Maxillofac Implants. 2009;24(4):712-9. PMID: 19885413 (opens in a new tab).
- Puisys A, Linkevicius T. The influence of mucosal tissue thickening on crestal bone stability around bone-level implants. A prospective controlled clinical trial. Clin Oral Implants Res. 2015;26(2):123-9. doi:10.1111/clr.12301 (opens in a new tab). PMID: 24313250 (opens in a new tab).
- Linkevicius T, Puisys A, Linkeviciene L, Peciuliene V, Schlee M. Crestal Bone Stability around Implants with Horizontally Matching Connection after Soft Tissue Thickening: A Prospective Clinical Trial. Clin Implant Dent Relat Res. 2015;17(3):497-508. doi:10.1111/cid.12155 (opens in a new tab). PMID: 24103157 (opens in a new tab).
- Puisys A, Vindasiute-Narbute E, Razukevicius D, Akhondi S, Gallucci GO, Pedrinaci I. Clinical efficacy of two vertical soft tissue augmentation techniques for peri-implant crestal bone level stability: A randomized clinical trial. Clin Implant Dent Relat Res. 2024;26(6):1086-1100. doi:10.1111/cid.13365 (opens in a new tab). PMID: 39128852 (opens in a new tab).
- Spinato S, Stacchi C, Lombardi T, Bernardello F, Messina M, Zaffe D. Biological width establishment around dental implants is influenced by abutment height irrespective of vertical mucosal thickness: A cluster randomized controlled trial. Clin Oral Implants Res. 2019;30(7):649-659. doi:10.1111/clr.13450 (opens in a new tab). PMID: 31033035 (opens in a new tab).
- Spinato S, Stacchi C, Lombardi T, Bernardello F, Messina M, Dovigo S, et al. Influence of abutment height and vertical mucosal thickness on early marginal bone loss around implants: A randomised clinical trial with an 18-month post-loading clinical and radiographic evaluation. Int J Oral Implantol (Berl). 2020;13(3):279-290. PMID: 32879932 (opens in a new tab).
- Muñoz M, Busoms E, Vilarrasa J, Albertini M, Ruíz-Magaz V, Nart J. Bone-level changes around implants with 1- or 3-mm-high abutments and their relation to crestal mucosal thickness: A 1-year randomized clinical trial. J Clin Periodontol. 2021;48(10):1302-1311. doi:10.1111/jcpe.13505 (opens in a new tab). PMID: 34101234 (opens in a new tab).
- Garaicoa-Pazmino C, Mendonça G, Ou A, Chan HL, Mailoa J, Suárez-López Del Amo F, et al. Impact of mucosal phenotype on marginal bone levels around tissue level implants: A prospective controlled trial. J Periodontol. 2021;92(6):771-783. doi:10.1002/JPER.20-0458 (opens in a new tab). PMID: 33107977 (opens in a new tab).
- Spinato S, Galindo-Moreno P, Bernardello F, Zaffe D. Minimum Abutment Height to Eliminate Bone Loss: Influence of Implant Neck Design and Platform Switching. Int J Oral Maxillofac Implants. 2018;33(2):405–411. doi:10.11607/jomi.5604 (opens in a new tab). PMID: 28817742 (opens in a new tab).
- Bressan E, Guazzo R, Tomasi C, Peña TG, Galindo-Moreno P, Caponio VCA, et al. Influence of soft tissue thickness on marginal bone level around dental implants: A systematic review with meta-analysis and trial-sequential analysis. Clin Oral Implants Res. 2023;34(5):405-415. doi:10.1111/clr.14032 (opens in a new tab). PMID: 36737243 (opens in a new tab).
- Tang P, Meng Z, Song X, Huang J, Su C, Li L. Influence of different mucosal phenotype on early and long-term marginal bone loss around implants: a systematic review and meta-analysis. Clin Oral Investig. 2023;27(4):1391-1407. doi:10.1007/s00784-023-04902-w (opens in a new tab). PMID: 36800027 (opens in a new tab).
- Akcalı A, Trullenque-Eriksson A, Sun C, Petrie A, Nibali L, Donos N. What is the effect of soft tissue thickness on crestal bone loss around dental implants? A systematic review. Clin Oral Implants Res. 2017;28(9):1046-1053. doi:10.1111/clr.12916 (opens in a new tab). PMID: 27432592 (opens in a new tab).
- Di Gianfilippo R, Valente NA, Toti P, Wang HL, Barone A. Influence of implant mucosal thickness on early bone loss: a systematic review with meta-analysis. J Periodontal Implant Sci. 2020;50(4):209-225. doi:10.5051/jpis.1904440222 (opens in a new tab). PMID: 32643328 (opens in a new tab).
- Del Amo FS, Romero-Bustillos M, Catena A, Galindo-Moreno P, Sánchez-Suárez JM, Sánchez R, et al. Effect of Abutment Height on Marginal Bone Loss Around Dental Implants: A Systematic Review. Int J Prosthodont. 2024;37(1):95-102. doi:10.11607/ijp.8174 (opens in a new tab). PMID: 38381988 (opens in a new tab).
- Lin GH, Lee E, Barootchi S, Rosen PS, Curtis D, Kan J, et al. The influence of prosthetic designs on peri-implant bone loss: An AO/AAP systematic review and meta-analysis. J Periodontol. 2025;96(6):634-651. doi:10.1002/JPER.24-0144 (opens in a new tab). PMID: 40489290 (opens in a new tab).
- Spinato S, Bernardello F, Lombardi T, Soardi CM, Messina M, Zaffe D, et al. Influence of apico-coronal positioning of tissue-level implants on marginal bone stability during supracrestal tissue height establishment: A multi-center prospective study. Clin Implant Dent Relat Res. 2022;24(5):611-620. doi:10.1111/cid.13128 (opens in a new tab). PMID: 36000363 (opens in a new tab).
- Spinato S, Bernardello F, Stacchi C, Soardi CM, Messina M, Rapani A, et al. Marginal Bone Changes Around Tissue-Level Implants After Prosthesis Delivery: A Multicenter Prospective Study. Clin Implant Dent Relat Res. 2025;27(3):e70071. doi:10.1111/cid.70071 (opens in a new tab). PMID: 40500982 (opens in a new tab).
- Linkevicius T, Puisys A, Linkevicius R, Alkimavicius J, Gineviciute E, Linkeviciene L. The influence of submerged healing abutment or subcrestal implant placement on soft tissue thickness and crestal bone stability. A 2-year randomized clinical trial. Clin Implant Dent Relat Res. 2020;22(4):497-506. doi:10.1111/cid.12903 (opens in a new tab). PMID: 32250061 (opens in a new tab).
- Abrahamsson I, Berglundh T, Lindhe J. The mucosal barrier following abutment dis/reconnection. An experimental study in dogs. J Clin Periodontol. 1997;24(8):568-72. doi:10.1111/j.1600-051x.1997.tb00230.x (opens in a new tab). PMID: 9266344 (opens in a new tab).
- Sanz-Sánchez I, Molina A, Martin C, Bollain J, Calatrava J, Sanz M. The effect of one-time abutment placement on clinical and radiographic outcomes: A 5-year randomized clinical trial. Clin Oral Implants Res. 2024;35(6):609-620. doi:10.1111/clr.14256 (opens in a new tab). PMID: 38506392 (opens in a new tab).
- Calatrava J, Sanz-Sánchez I, Molina A, Bollain J, Martín C, Sanz M. Effect of one-time placement of the definitive abutment versus multiple healing abutment disconnections and reconnections during the prosthetic phase on radiographic and clinical outcomes: A 12-month randomized clinical trial. Clin Implant Dent Relat Res. 2024;26(5):998-1011. doi:10.1111/cid.13361 (opens in a new tab). PMID: 39011816 (opens in a new tab).
- Quintas-Hijós J, Pérez-Pevida E. Influence of intermediate abutment height and timing of placement on marginal bone loss in single implant-supported crowns: a 12-month follow-up randomized clinical trial. Clin Oral Investig. 2025;29(6):291. doi:10.1007/s00784-025-06364-8 (opens in a new tab). PMID: 40335732 (opens in a new tab).
- Tajti P, Solyom E, Váncsa S, Mátrai P, Hegyi P, Varga G, et al. Less marginal bone loss around bone-level implants restored with long abutments: A systematic review and meta-analysis. Periodontol 2000. 2024;94(1):627-638. doi:10.1111/prd.12534 (opens in a new tab). PMID: 37766634 (opens in a new tab).
- Pelekos G, Chin B, Wu X, Fok MR, Shi J, Tonetti MS. Association of crown emergence angle and profile with dental plaque and inflammation at dental implants. Clin Oral Implants Res. 2023;34(10):1047-1057. doi:10.1111/clr.14134 (opens in a new tab). PMID: 37461128 (opens in a new tab).
- Ashurko I, Bokareva S, Svitich O, Tarasenko S, Kompaniets D, Avagyan A, et al. Depth of implant mucosal tunnel influences its microbiota: a prospective observational cross-sectional study. BMC Oral Health. 2026;26(1). doi:10.1186/s12903-026-09312-4 (opens in a new tab). PMID: 42469774 (opens in a new tab).
- Yin W, Yang Y, Bao R, Chen X. Necessity of removing implant-supported prostheses when conducting supportive peri-implant therapy: A clinical study. J Prosthet Dent. 2025;134(6):2239-2245. doi:10.1016/j.prosdent.2024.09.021 (opens in a new tab). PMID: 39542794 (opens in a new tab).
- Discepoli N, De Rubertis I, David D, Ferrari A, Mirra R. Influence of Emergence Angle and Mucosal Tunnel Depth on Artificial Biofilm Removal Around Dental Implants: An In Vitro Study. Int J Dent. 2025;2025:7500003. doi:10.1155/ijod/7500003 (opens in a new tab). PMID: 41262745 (opens in a new tab).
- Sabri H, Hazrati P, Tavelli L, Garaicoa-Pazmino C, Calatrava J, Wang HL, et al. Impact of Peri-Implant Phenotype on Implant Therapy Outcomes: A 5-Year Cohort Analysis on Soft Tissue-Level Implants. J Clin Periodontol. 2026;53(3):394-406. doi:10.1111/jcpe.70062 (opens in a new tab). PMID: 41387987 (opens in a new tab).
- Muñoz M, Pardo G, Vilarrasa J, Babiano Á, Ruíz-Magaz V, Nart J. Long-Term Impact of 1-mm Versus 3-mm Definitive Abutments on Marginal Bone Loss and Peri-Implant Disease: A 7-Year Randomised Clinical Trial. J Clin Periodontol. 2025;52(11):1595-1604. doi:10.1111/jcpe.70009 (opens in a new tab). PMID: 40827015 (opens in a new tab).
- Lin CY, Kuo PY, Chiu MY, Wang HL. Depth of mucosal tunnel in peri-implant health during 12-month follow-up in patients with controlled periodontitis. J Periodontol. 2023;94(1):66-76. doi:10.1002/JPER.21-0680 (opens in a new tab). PMID: 35661355 (opens in a new tab).
- Zhang Z, Shi D, Meng H, Han J, Zhang L, Li W. Influence of vertical soft tissue thickness on occurrence of peri-implantitis in patients with periodontitis: a prospective cohort study. Clin Implant Dent Relat Res. 2020;22(3):292-300. doi:10.1111/cid.12896 (opens in a new tab). PMID: 32250044 (opens in a new tab).
- Puisys A, Janda M, Auzbikaviciute V, Gallucci GO, Mattheos N. Contour angle and peri-implant tissue height: Two interrelated features of the implant supracrestal complex. Clin Exp Dent Res. 2023;9(3):418-424. doi:10.1002/cre2.731 (opens in a new tab). PMID: 36988518 (opens in a new tab).
- Wang HL, Avila-Ortiz G, Monje A, Kumar P, Calatrava J, Aghaloo T, et al. AO/AAP consensus on prevention and management of peri-implant diseases and conditions: Summary report. J Periodontol. 2025;96(6):519-541. doi:10.1002/JPER.25-0270 (opens in a new tab). PMID: 40501397 (opens in a new tab).
- Albrektsson T, Zarb G, Worthington P, Eriksson AR. The long-term efficacy of currently used dental implants: a review and proposed criteria of success. Int J Oral Maxillofac Implants. 1986;1(1):11-25. PMID: 3527955 (opens in a new tab).

